BRPI1008532A2 - "composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii". - Google Patents
"composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii".Info
- Publication number
- BRPI1008532A2 BRPI1008532A2 BRPI1008532A BRPI1008532A BRPI1008532A2 BR PI1008532 A2 BRPI1008532 A2 BR PI1008532A2 BR PI1008532 A BRPI1008532 A BR PI1008532A BR PI1008532 A BRPI1008532 A BR PI1008532A BR PI1008532 A2 BRPI1008532 A2 BR PI1008532A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- type iii
- based compositions
- domain type
- fibronectin domain
- Prior art date
Links
- 102000016359 Fibronectins Human genes 0.000 title 1
- 108010067306 Fibronectins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15198709P | 2009-02-12 | 2009-02-12 | |
| US61/151,987 | 2009-02-12 | ||
| PCT/US2010/023625 WO2010093627A2 (en) | 2009-02-12 | 2010-02-09 | Fibronectin type iii domain based scaffold compositions, methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1008532A2 true BRPI1008532A2 (pt) | 2018-04-03 |
| BRPI1008532B1 BRPI1008532B1 (pt) | 2021-12-14 |
Family
ID=42562254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1008532-7A BRPI1008532B1 (pt) | 2009-02-12 | 2010-02-09 | Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8293482B2 (pt) |
| EP (1) | EP2396011B1 (pt) |
| JP (1) | JP5873335B2 (pt) |
| CN (1) | CN102596992B (pt) |
| AU (1) | AU2010213892B2 (pt) |
| BR (1) | BRPI1008532B1 (pt) |
| CA (1) | CA2752211C (pt) |
| DK (1) | DK2396011T3 (pt) |
| IL (1) | IL214539A (pt) |
| MX (1) | MX2011008566A (pt) |
| RU (1) | RU2562700C2 (pt) |
| WO (1) | WO2010093627A2 (pt) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06006406A (es) | 2003-12-05 | 2007-03-21 | Adnexus Therapeutics Inc | Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2. |
| MX2009005466A (es) | 2006-11-22 | 2009-08-17 | Adnexus A Bristol Myers Sqibb | Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i. |
| BRPI0818810A2 (pt) | 2007-10-31 | 2014-10-29 | Medimmune Llc | Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável. |
| WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
| JP2011520961A (ja) | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | 多価フィブロネクチンをベースとする足場ドメインタンパク質 |
| EP3128048B1 (en) | 2008-10-31 | 2018-11-28 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| WO2011130324A1 (en) | 2010-04-13 | 2011-10-20 | Medimmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
| RU2767543C2 (ru) | 2010-04-30 | 2022-03-17 | Янссен Байотек, Инк. | Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| EP3091028A1 (en) | 2010-05-26 | 2016-11-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| PL2675479T3 (pl) | 2011-02-15 | 2016-09-30 | Cytotoksyczne pochodne benzodiazepiny | |
| ES2676499T3 (es) | 2011-04-13 | 2018-07-20 | Bristol-Myers Squibb Company | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones |
| US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
| WO2012158739A1 (en) | 2011-05-17 | 2012-11-22 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
| SG195172A1 (en) | 2011-06-21 | 2013-12-30 | Immunogen Inc | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| CN103827361A (zh) | 2011-09-27 | 2014-05-28 | 詹森生物科技公司 | 具有可供选择的结合表面的基于iii型纤连蛋白重复的蛋白质支架 |
| KR102132997B1 (ko) | 2011-10-11 | 2020-07-14 | 메디뮨 엘엘씨 | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| EP2773659A2 (en) | 2011-10-31 | 2014-09-10 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
| CA2874646C (en) | 2012-05-25 | 2020-12-01 | Janssen Biotech, Inc. | Non-natural consensus albumin binding domains |
| EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| AU2013315482B2 (en) | 2012-09-13 | 2018-03-15 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
| EP3406629B1 (en) * | 2013-02-06 | 2020-06-24 | Bristol-Myers Squibb Company | Fibronectin type iii domain proteins with enhanced solubility |
| EP3617220B1 (en) | 2013-02-12 | 2021-03-24 | Bristol-Myers Squibb Company | High ph protein refolding methods |
| EP2956468B1 (en) | 2013-02-12 | 2020-06-10 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
| HK1219423A1 (zh) | 2013-02-28 | 2017-04-07 | Immunogen, Inc. | 包含细胞结合剂及细胞毒素剂的轭合物 |
| EP2961434A2 (en) | 2013-02-28 | 2016-01-06 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| EP2968587A2 (en) | 2013-03-13 | 2016-01-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2015023927A2 (en) * | 2013-08-16 | 2015-02-19 | University Of Rochester | Composition and method for detection of nanomaterials |
| ES2898273T3 (es) | 2014-03-20 | 2022-03-04 | Bristol Myers Squibb Co | Moléculas con una estructura a base de fibronectina estabilizada |
| SG11201607820QA (en) | 2014-03-20 | 2016-10-28 | Bristol Myers Squibb Co | Serum albumin-binding fibronectin type iii domains |
| WO2016029220A1 (en) * | 2014-08-22 | 2016-02-25 | Nectagen, Inc. | Affinity proteins and uses thereof |
| EA034138B1 (ru) | 2014-09-03 | 2020-01-09 | Иммуноджен, Инк. | Цитотоксические бензодиазепиновые производные |
| JP2017527562A (ja) | 2014-09-03 | 2017-09-21 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体 |
| MX385081B (es) | 2014-11-25 | 2025-03-14 | Bristol Myers Squibb Co | Métodos y composiciones para radioetiquetado con 18f de productos biológicos. |
| AU2016228806B2 (en) | 2015-03-12 | 2020-10-22 | Medimmune, Llc | Method of purifying albumin-fusion proteins |
| EA201890513A1 (ru) | 2015-08-17 | 2018-11-30 | Янссен Фармацевтика Нв | Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение |
| WO2017053617A1 (en) | 2015-09-23 | 2017-03-30 | Bristol-Myers Squibb Company | Fast-off rate serum albumin binding fibronectin type iii domains |
| KR20180072820A (ko) | 2015-11-02 | 2018-06-29 | 얀센 파마슈티카 엔.브이. | 항-il1rap 항체, il1rap 및 cd3과 결합하는 이중특이성 항원 결합 분자, 및 그의 용도 |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| SG11201810687SA (en) * | 2016-06-03 | 2018-12-28 | Janssen Biotech Inc | Serum albumin-binding fibronectin type iii domains |
| TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| RU2759952C2 (ru) | 2016-12-14 | 2021-11-19 | Янссен Байотек, Инк. | Cd8a-связывающие домены типа iii фибронектина |
| AU2018229277B2 (en) | 2017-02-28 | 2025-03-20 | Immunogen, Inc. | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
| KR20220080044A (ko) | 2018-05-16 | 2022-06-14 | 얀센 바이오테크 인코포레이티드 | 암 요법에 사용하기 위한 bcma/cd3 및 gprdc5d/cd3 이중특이성 항체 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| JP2022527449A (ja) | 2019-03-21 | 2022-06-02 | イミュノジェン・インコーポレーテッド | 細胞結合剤－薬物複合体の調製方法 |
| US20230094471A1 (en) | 2019-03-29 | 2023-03-30 | Immunogen, Inc. | Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases |
| ES2966473T3 (es) | 2019-04-26 | 2024-04-22 | Immunogen Inc | Derivados de camptotecina |
| BR112022000145A2 (pt) | 2019-07-12 | 2022-02-22 | Janssen Pharmaceutica Nv | Agentes de ligação e usos dos mesmos |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| WO2021076546A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| CA3161723A1 (en) | 2019-12-18 | 2021-06-24 | Karyn O'neil | Serum albumin-binding fibronectin type iii domains and uses thereof |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| EP4110407A1 (en) | 2020-02-28 | 2023-01-04 | Bristol-Myers Squibb Company | Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof |
| WO2021207305A1 (en) * | 2020-04-08 | 2021-10-14 | Nostrum Pharmaceuticals, Llc | Compositions and methods using interferon for treating viral respiratory infections |
| AU2021272291A1 (en) | 2020-05-11 | 2023-02-02 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| CN111588837B (zh) * | 2020-05-14 | 2023-06-06 | 中南大学湘雅三医院 | 一种蛋白-纳米银复合物的制备方法及制备的复合物和用途 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| JP2024506694A (ja) | 2021-02-16 | 2024-02-14 | ヤンセン バイオテツク，インコーポレーテツド | 増強されたリンカー標的化のための材料及び方法 |
| JP2024507180A (ja) | 2021-02-16 | 2024-02-16 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体 |
| US12103977B2 (en) | 2021-03-24 | 2024-10-01 | Janssen Biotech, Inc. | Trispecific antibody targeting CD79b, CD20, and CD3 |
| AR125212A1 (es) | 2021-03-24 | 2023-06-28 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas |
| EP4314055A1 (en) | 2021-03-24 | 2024-02-07 | Janssen Biotech, Inc. | Antibody targeting cd22 and cd79b |
| KR20240034160A (ko) | 2021-04-14 | 2024-03-13 | 에이알오 바이오테라퓨틱스 컴패니 | Cd71 결합 피브로넥틴 3형 도메인 |
| AU2022258584A1 (en) | 2021-04-14 | 2023-10-12 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| EP4426437A4 (en) | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
| WO2025233825A1 (en) | 2024-05-06 | 2025-11-13 | Janssen Pharmaceutica Nv | Enrichment of cells expressing a bird linker |
| WO2025243243A1 (en) | 2024-05-24 | 2025-11-27 | Janssen Biotech, Inc. | Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
| FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
| US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
| US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
| US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
| US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
| US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
| US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| EP0494955B1 (en) | 1989-10-05 | 1998-07-15 | Optein, Inc. | Cell-free synthesis and isolation of novel genes and polypeptides |
| US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1991018980A1 (en) | 1990-06-01 | 1991-12-12 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
| WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| EP0572529A4 (en) | 1991-02-21 | 1994-11-02 | Gilead Sciences Inc | SPECIFIC APTAMER OF BIOMOLECULES AND PROCESS FOR PRODUCING THE SAME. |
| US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| ES2284226T3 (es) | 1991-07-02 | 2007-11-01 | Nektar Therapeutics | Dispositivo para proporcionar medicamentos en aerosol. |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| WO1994006498A1 (en) | 1992-09-23 | 1994-03-31 | Fisons Plc | Inhalation device |
| WO1994008552A2 (en) | 1992-10-19 | 1994-04-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
| US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
| WO1994016970A1 (en) | 1993-01-19 | 1994-08-04 | Glaxo Group Limited | Device |
| WO1994018317A1 (en) | 1993-02-12 | 1994-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
| TR199801265T2 (xx) | 1996-01-03 | 1998-10-21 | Glaxo Group Limited | ��e soluma cihaz�. |
| US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
| US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
| IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
| WO1998056915A2 (en) * | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| KR100589926B1 (ko) | 1997-09-29 | 2006-06-15 | 넥타르 테라퓨틱스 | 천공된 미립자 및 사용 방법 |
| US7115396B2 (en) * | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| EP2385067A1 (en) * | 2000-07-11 | 2011-11-09 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| EP1356075A4 (en) * | 2000-10-16 | 2005-04-13 | Compound Therapeutics Inc | PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS |
| AU2003299817A1 (en) * | 2002-12-20 | 2004-07-22 | Applera Corporation | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof |
| US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| EP3128048B1 (en) * | 2008-10-31 | 2018-11-28 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
-
2010
- 2010-02-09 RU RU2011137464/10A patent/RU2562700C2/ru active
- 2010-02-09 JP JP2011550185A patent/JP5873335B2/ja not_active Expired - Fee Related
- 2010-02-09 WO PCT/US2010/023625 patent/WO2010093627A2/en not_active Ceased
- 2010-02-09 MX MX2011008566A patent/MX2011008566A/es active IP Right Grant
- 2010-02-09 AU AU2010213892A patent/AU2010213892B2/en not_active Ceased
- 2010-02-09 DK DK10741624.0T patent/DK2396011T3/en active
- 2010-02-09 EP EP10741624.0A patent/EP2396011B1/en active Active
- 2010-02-09 BR BRPI1008532-7A patent/BRPI1008532B1/pt not_active IP Right Cessation
- 2010-02-09 CN CN201080017059.1A patent/CN102596992B/zh not_active Expired - Fee Related
- 2010-02-09 CA CA2752211A patent/CA2752211C/en active Active
- 2010-02-12 US US12/704,824 patent/US8293482B2/en active Active
-
2011
- 2011-08-09 IL IL214539A patent/IL214539A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN102596992B (zh) | 2015-09-09 |
| BRPI1008532B1 (pt) | 2021-12-14 |
| EP2396011A2 (en) | 2011-12-21 |
| IL214539A0 (en) | 2011-09-27 |
| JP2012517240A (ja) | 2012-08-02 |
| AU2010213892B2 (en) | 2014-10-23 |
| JP5873335B2 (ja) | 2016-03-01 |
| EP2396011A4 (en) | 2012-10-24 |
| IL214539A (en) | 2015-01-29 |
| WO2010093627A3 (en) | 2010-10-14 |
| AU2010213892A1 (en) | 2011-09-01 |
| CA2752211A1 (en) | 2010-08-19 |
| MX2011008566A (es) | 2011-11-29 |
| US20100255056A1 (en) | 2010-10-07 |
| RU2562700C2 (ru) | 2015-09-10 |
| RU2011137464A (ru) | 2013-03-20 |
| US8293482B2 (en) | 2012-10-23 |
| CN102596992A (zh) | 2012-07-18 |
| CA2752211C (en) | 2020-03-24 |
| DK2396011T3 (en) | 2016-04-25 |
| EP2396011B1 (en) | 2016-04-13 |
| WO2010093627A2 (en) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1008532A2 (pt) | "composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii". | |
| BRPI0919881A2 (pt) | composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii | |
| BRPI1008709A2 (pt) | composições e usos das mesmas. | |
| BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
| BRPI0807896A2 (pt) | Fórceps bipolares não-aderentes. | |
| BRPI0913447A2 (pt) | composição de éster, e, composição para cuidado pessoal. | |
| BRPI0811993A2 (pt) | " hetarilanilinas como moduladores para beta-amiloide ". | |
| EP2513022A4 (en) | AZEOTROPENEAN COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUOR-2-BUTENE | |
| BRPI1014583A2 (pt) | sulfonamidas heterocíclicos, composições farmacêuticas e usos do mesmo. | |
| BRPI0922384A2 (pt) | "manipulador de suprimento para equipamento". | |
| BRPI0809795A2 (pt) | "antagonistas do trpv1 e usos deste". | |
| FR2934650B1 (fr) | Generateur d'energie. | |
| BRPI0822337A2 (pt) | Folatos, composições e usos dos mesmos | |
| EP2438989A4 (en) | ASYMMETRIC HYDROGENATION CATALYST | |
| MX379016B (es) | Composiciones y metodos para tratar enfermedad de gaucher. | |
| BRPI1009372A2 (pt) | compostos, composição farmacêutica e respectivos usos | |
| BRPI1006974A2 (pt) | "uso de absorvedores de uv, e, composição cosmética." | |
| UY33125A (es) | Diaza-espiro-[5,5]-undecanos | |
| BRPI1007929A2 (pt) | "métodos e composições para o tratamento de neovascularização". | |
| BRPI0813922A2 (pt) | composições de inibição de influenza e métodos. | |
| BRPI1011460A2 (pt) | Composição desinfetante. | |
| BRPI0916060A2 (pt) | "interconector para fluidos" | |
| BR112012000379A2 (pt) | composições de matriz carreadora, métodos e usos | |
| BRPI0810265A2 (pt) | "vagão ferroviáriio do tipo plataforma". | |
| BRPI0910378A2 (pt) | composições imunogênicas anti-amilóides, métodos e usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2813 DE 03-12-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |